Dr. Stephen Spielberg to Host Prominent Professionals at DIA EuroMeeting 2013
News Feb 28, 2013
Dr. Stephen Spielberg, M.D., Ph.D., Editor-in-Chief of DIA’s peer-reviewed scientific journal, Therapeutic Innovation & Regulatory Science (TIRS), will be meeting high-profile industry experts from around the world at DIA Europe’s 25th Annual EuroMeeting in Amsterdam from 4-6 March, 2013.
Dr. Spielberg will welcome EuroMeeting 2013 participants at the DIA’s exhibition booth on Monday 4 March.
Then, on 6 March, a host of prominent industry experts, including representatives from the European Medicines Agency (EMA) and the Directorate General for Health and Consumer Affairs (DG SANCO), will be invited to a meet and greet breakfast and a TIRS Editorial lunch.
Dr. Spielberg said: “I am greatly looking forward to welcoming participants to the EuroMeeting 2013 in Amsterdam. This year promises to be an insightful event with 110 comprehensive sessions.”
More than 300 high-profile speakers, moderators, and panelists from around the world are set to attend EuroMeeting 2013, substantiating the meeting’s claim to being the most important event in the medicines development calendar.
The meeting will feature 200 exhibitors and bring together professionals from the biopharmaceutical industry, contract research and service organizations, academic research centres, health ministries, and delegates from patient organizations to share knowledge focusing on better public health protection, greater transparency of processes, and the rational use of medicinal products.
For more information about the event visit www.diahome.org/EM2013.
Pioneering Method Enables Screening Millions of Human Antibodies for Rapid Therapeutic DiscoveryNews
A paper just published in Nature Biotechnology outlines a pioneering method of screening a person's diverse set of antibodies for rapid therapeutic discovery.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE